Biocrates Life Sciences GmbH and Pfizer Inc. have completed a preclinical pilot study to reveal candidate biomarkers for early events in vascular injury. Results will be presented at the conference Metabolic Markers for Drug Development and Clinical Studies Dec 4-5, 2006 in Florida.
"Our targeted and quantitative approach to metabolomics allows one to immediately deduce biologically relevant information from the analytical data", says Klaus Weinberger Ph D., CSO of Biocrates. "Important enzymatic reactions and selected metabolic pathways can be monitored on a fully standardized basis." Pfizer and Biocrates are currently discussing future collaborations for novel biomarker development in preclinical and clinical programs. This will allow Biocrates to validate and expand their innovative metabolomics approach with the world's largest pharmaceutical company.
Pfizer Inc, founded in 1849, is dedicated to better health and greater access to healthcare for people and their valued animals. Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment; consistent high-quality manufacturing of medicines, consumer products; and global leadership in corporate responsibility.
Biocrates, the leader in targeted metabolomics, pioneered an integrated mass spectrometry-based technology platform for rapidly extracting detailed information residing in metabolic networks.